Last reviewed 2026-04-20 · How we verify

Pradaxa (dabigatran-etexilate)

Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development.

Dabigatran etexilate is a direct thrombin inhibitor indicated for stroke prevention in atrial fibrillation, treatment and recurrence prevention of DVT/PE in adults, post-hip replacement prophylaxis, and VTE treatment in pediatric patients. The drug exhibits dose-proportional pharmacokinetics with 3-7% bioavailability, 12-17 hour half-life, and primarily renal elimination. Major risks include active bleeding, mechanical prosthetic valves, and significant drug interactions with P-glycoprotein inhibitors in renal impairment. Dabigatran represents an important oral anticoagulant option with broad clinical applications across multiple thromboembolic indications.

At a glance

Mechanism of action

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors that bind to and inhibit thrombin, a serine protease central to the coagulation cascade. By inhibiting thrombin, dabigatran prevents the conversion of fibrinogen into fibrin, thereby blocking thrombus development. The drug inhibits both free and clot-bound thrombin, as well as thrombin-induced platelet aggregation, providing comprehensive anticoagulant activity.

Approved indications

• Reduction of stroke and systemic embolism risk in non-valvular AF
• Treatment of DVT and PE in adults
• Reduction of DVT and PE recurrence in adults
• Prophylaxis of DVT and PE after hip replacement surgery
• Treatment of VTE in pediatric patients
• Reduction of VTE recurrence in pediatric patients

Boxed warnings

• WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules , increases the risk of thrombotic events. If anticoagulation with dabigatran etexilate capsules a re discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.6, 2.7, 2.8) and Warnings and Precautions (5.1)]. (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with dabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of dabigatran etexilate capsules and neuraxial procedures is not known [see Warnings and Precautions (5.3)]. Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.3)]. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions (5.3)]. WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning (A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if dabigatran etexilate capsules are discontinued for a reason other than pathological bleeding or completion of a course of therapy ( 2.6 , 2.7 , 2.8 , 5.1 ). (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with dabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis ( 5.3 ). Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated ( 5.3 ).

Common side effects

• Haematoma
• Phlebitis
• Vertigo
• Conjunctival haemorrhage
• Abdominal pain
• Diarrhoea
• Flatulence
• Nausea
• Chills
• Influenza like illness
• Mucosal inflammation
• Rhinitis

Drug interactions

• P-gp inducers (e.g., rifampin)
• P-gp inhibitors (dronedarone, systemic ketoconazole) in moderate renal impairment
• P-gp inhibitors (verapamil, amiodarone, quinidine, clarithromycin, ticagrelor)
• P-gp inhibitors in severe renal impairment

Key clinical trials

• Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
• FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
• PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
• Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
• Anticoagulation in Patients With Venous Thromboembolism and Cancer
• High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
• A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects (PHASE1)
• SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pradaxa CI brief — competitive landscape report
• Pradaxa updates RSS · CI watch RSS
• Boehringer Ingelheim portfolio CI